{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064983","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.880525+00:00","generated_at":"2026-05-22T07:16:29.137735+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA","bullets":["Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.","Cash, equivalents, and marketable securities $318.2M; runway into 2027 past Phase 3 topline data expected 2H 2026.","LUGANO trial >90% enrolled, LUCIA >50%; enrollment on track to complete 2H 2025.","Phase 2 VERONA in DME met endpoints; subgroup showed BCVA +10.3 letters vs +3.0 for aflibercept at week 24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064983","json":"https://secwatch.observer/filing/0000950170-25-064983.json","markdown":"https://secwatch.observer/filing/0000950170-25-064983.md","text":"https://secwatch.observer/filing/0000950170-25-064983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/0000950170-25-064983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/eypt-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:16:29.137735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}